Methods of treating psoriatic arthritis using IL-17 antagonists
The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
1. A method of treating Psoriatic Arthritis (PsA), comprising:
a) subcutaneously administering to a patient having PsA five doses of about 150 mg-about 300 mg of an IL-17 antibody, each of the five doses being delivered weekly; and
b) thereafter, subcutaneously administering to the patient a dose of about 150 mg-about 300 mg of the IL-17 antibody every month, wherein the IL-17 antibody comprises:
i) an immunoglobulin V H domain comprising the amino acid sequence set forth as SEQ ID NO:8 and an immunoglobulin V L domain comprising the amino acid sequence set forth as SEQ ID NO:10;
ii) an immunoglobulin V H domain comprising the hypervariable regions comprising the amino acid sequences set forth as SEQ ID NOs:1-3, respectively, and an immunoglobulin V L domain comprising the hypervariable regions comprising the amino acid sequences set forth as SEQ ID NOs:4-6, respectively; or
iii) an immunoglobulin V H domain comprising the hypervariable regions comprising the amino acid sequences set forth as SEQ ID NOs:11-13, respectively, and an immunoglobulin V L domain comprising the hypervariable regions comprising the amino acid sequences set forth as SEQ ID NOs:4-6, respectively.
2. The method according to claim 1 , wherein the IL-17 antibody is secukinumab.
3. The method according to claim 1 , wherein, prior to treatment with the IL-17 antibody, the patient had an inadequate response to, had failure to, or was intolerant to treatment with a TNF alpha antagonist.
4. The method according to claim 1 , wherein the patient has co-existing moderate to severe plaque psoriasis.
5. The method according to claim 1 , further comprising administering a DMARD to the patient.
6. The method according to claim 5 , wherein the DMARD is methotrexate.
7. A method of treating PsA in a patient, comprising administering about 150 mg—about 300 mg of secukinumab by subcutaneous injection to the patient at weeks 0, 1, 2, 3 and 4, followed by about 150 mg—about 300 mg of secukinumab every 4 weeks.
8. The method according to claim 7 , wherein the patient has active PsA.
9. The method according to claim 7 , wherein, prior to treatment with secukinumab, the patient had an inadequate response to, had failure to, or was intolerant to treatment with a TNF alpha antagonist.
10. The method according to claim 7 , wherein the patient has co-existing moderate to severe plaque psoriasis.
11. The method according to claim 7 , further comprising administering a DMARD to the patient.
12. The method according to claim 11 , wherein the DMARD is methotrexate.
13. The method according to claim 7 , comprising administering about 300 mg of secukinumab by subcutaneous injection to the patient at weeks 0, 1, 2, 3 and 4, followed by 300 mg of secukinumab every 4 weeks.
14. The method according to claim 13 , wherein the patient has active PsA.
15. The method according to claim 13 , wherein, prior to treatment with secukinumab, the patient responded inadequately to treatment with at least one DMARD.
16. The method according to claim 13 , wherein, prior to treatment with secukinumab, the patient had an inadequate response to, had failure to, or was intolerant to treatment with a TNF alpha antagonist.
17. The method according to claim 13 , wherein the patient has co-existing moderate to severe plaque psoriasis.
18. The method according to claim 13 , further comprising administering a DMARD to the patient.
19. The method according to claim 18 , wherein the DMARD is methotrexate.
20. The method according to claim 7 , comprising administering about 150 mg of secukinumab by subcutaneous injection to the patient at weeks 0, 1, 2, 3 and 4, followed by 150 mg of secukinumab every 4 weeks.
21. The method according to claim 20 , wherein the patient has active PsA.
22. The method according to claim 20 , wherein, prior to treatment with secukinumab, the patient responded inadequately to treatment with at least one DMARD.
23. The method according to claim 20 , wherein, prior to treatment with secukinumab, the patient had an inadequate response to, had failure to, or was intolerant to treatment with a TNF alpha antagonist.
24. The method according to claim 20 , wherein the patient has co-existing moderate to severe plaque psoriasis.
25. The method according to claim 20 , further comprising administering a DMARD to the patient.
26. The method according to claim 25 , wherein the DMARD is methotrexate.